ArticleCureus2026
Molecular Mechanisms of Carbapenem Resistance in Clinical Enterobacterales Isolates: The Role of Carbapenemases and Porin Loss.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Carbapenem-resistant Enterobacterales (CRE) have emerged as a major global public health threat, driven by the rapid dissemination of carbapenemase genes that compromise the efficacy of last-line antimicrobial agents. Comprehensive characterization of these mechanisms is essential for informing antimicrobial stewardship and infection-control strategies. The objective of this study was to investigate the molecular mechanisms underlying carbapenem resistance among clinical Enterobacterales isolates, with particular emphasis on carbapenemase genes and outer membrane porin expression alterations. Methods A retrospective cross-sectional study was conducted on 120 non-duplicate CRE isolates recovered from clinical specimens at a tertiary care hospital in Rajasthan, India, between January 2024 and December 2025. Species identification was performed using MALDI-TOF mass spectrometry, while antimicrobial susceptibility testing and carbapenem minimum inhibitory concentration (MIC) determination were carried out according to CLSI guidelines. Carbapenemase production was assessed using the Carba NP test. PCR was used to detect major carbapenemase and extended-spectrum β-lactamase (ESBL) genes. Outer membrane porin expression was evaluated by SDS-PAGE with densitometric analysis. Results
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.